N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸
![N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 结构式](https://img.chemicalbook.com/CAS/GIF/199850-67-4.gif)
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 性质
| 熔点 | 192-193℃ |
|---|---|
| 密度 | 1.457 |
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | DMF：50mg/mL； DMSO：50mg/mL； DMSO:PBS (pH 7.2) (1:1)：0.5 mg/ml；乙醇：10mg/mL |
| 形态 | 结晶固体 |
| 颜色 | 白至粉红 |
| InChI | 1S/C17H18BrNO4S/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12/h3-11,16,19H,1-2H3,(H,20,21)/t16-/m0/s1 |
| InChIKey | GJOCABIDMCKCEG-INIZCTEOSA-N |
| SMILES | [S](=O)(=O)(N[C@@H](C(C)C)C(=O)O)c1ccc(cc1)c2ccc(cc2)Br |
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 用途与合成方法
|
MMP-2 4 nM (IC 50 ) |
MMP-3 7 nM (IC 50 ) |
MMP-13 8 nM (IC 50 ) |
MMP-1 6.0 μM (IC 50 ) |
MMP-7 7.2 μM (IC 50 ) |
MMP-9 7.9 μM (IC 50 ) |
PD-166793 (0.1 μM) leads to a 20% inhibition of AMP deaminase (AMPD) activity in rat heart homogenates.
PD-166793 (100 μM; 36 h) significantly reduces MMP‐9 activity in normal human cardiac fibroblasts.
PD-166793 (1 mg/kg/d; daily gavage for 10 weeks) largely prevents the adverse remodeling characteristically seen in the aortocaval (AV) fistula model.
PD-166793 (5 mg/kg; oral gavage) exhibits superior pharmacokinetics (t
1/2
=43.6 h, C
max
=42.4 µg/mL, AUC
0-∞
=2822 µg•h/mL) in rats.
| Animal Model: | Male Sprague-Dawley rats (6 weeks) were induced chronic biventricular volume overload |
| Dosage: | 1 mg/kg |
| Administration: | Daily gavage beginning 2 weeks before surgery and continued until 8 weeks after surgery |
| Result: | Prevented ventricular dilatation and attenuated the hypertrophy typically induced by chronic volume overload. |
N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-107428 | N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 | 199850-67-4 | 5mg | 469 |
| 2026-09-15 | HY-107428 | N-[(4'-溴[1,1'-联苯]-4-基)磺酰基]-L-缬氨酸 | 199850-67-4 | 10 mM * 1 mLin DMSO | 515 |
